Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.

Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of ...

Exploring alternative vaccine delivery systems could increase accessibility and encourage those who fear needles to receive ...

In a small study, Yale researchers have found "differences in immune profiles" among those who have rare reaction to the ...

I could discuss risks and benefits in a more sophisticated way if I better understood a patient’s risk versus their ...